{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Curis, Inc."},"Symbol":{"label":"Symbol","value":"CRIS"},"Address":{"label":"Address","value":"128 SPRING STREET,BUILDING C - SUITE 500, LEXINGTON, Massachusetts, 02421, United States"},"Phone":{"label":"Phone","value":"+1 617 503-6500"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge."},"CompanyUrl":{"label":"Company Url","value":"https://www.curis.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"James E. Dentzer","title":"President, Chief Executive Officer & Director"},{"name":"Kimberly Steinmann","title":"Vice President-Clinical Development"},{"name":"Mark W. Noel","title":"VP-Technology Management & Intellectual Property"},{"name":"Robert E. Martell","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}